US6047491013
US6047491013
Mirum Pharmaceuticals, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 65/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±51.6% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.6x).
Beta (Market Relation)
0.62x
DefensiveVolatility (5Y p.a.)
51.6% p.a.
5-Year HorizonMax Drawdown (5Y)
-40.3%
5-Year HorizonSharpe Ratio
0.67
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +11.7% |
| 3 Years | 47.6% | -38.4% | 0.76 | +38.8% |
| 5 Years | 51.6% | -40.3% | 0.67 | +37.3% |
| 10 Years | — | — | — | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (51.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -40.3% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
9 ISS Score: 9 / 10
Audit Risk
6 ISS Score: 6 / 10
Board Risk
10 ISS Score: 10 / 10
Short Ratio
12.50